高级搜索
新辅助化疗在Ib~IIb期宫颈癌病例中的作用[J]. 肿瘤防治研究, 2003, 30(05): 428-429. DOI: 10.3971/j.issn.1000-8578.2118
引用本文: 新辅助化疗在Ib~IIb期宫颈癌病例中的作用[J]. 肿瘤防治研究, 2003, 30(05): 428-429. DOI: 10.3971/j.issn.1000-8578.2118
Neoadjuvant chemotherapy in stage Ib~IIb carcinoma of the cervix:long-term follow-up[J]. Cancer Research on Prevention and Treatment, 2003, 30(05): 428-429. DOI: 10.3971/j.issn.1000-8578.2118
Citation: Neoadjuvant chemotherapy in stage Ib~IIb carcinoma of the cervix:long-term follow-up[J]. Cancer Research on Prevention and Treatment, 2003, 30(05): 428-429. DOI: 10.3971/j.issn.1000-8578.2118

新辅助化疗在Ib~IIb期宫颈癌病例中的作用

Neoadjuvant chemotherapy in stage Ib~IIb carcinoma of the cervix:long-term follow-up

  • 摘要: 目的 探讨 1周期的新辅助化疗在宫颈癌病例治疗中的作用和地位。方法  4 9例Ib~IIb期宫颈癌病例在实施宫颈癌根治术前给予 1周期新辅助化疗组 (NAC)。结果 临床有效率 6 1.2 2 %。病理证实的完全缓解 2例。平均生存时间 4 4月。结论  1周期的新辅助化疗能够产生较高的有效率, 提高IIb期宫颈癌病例的手术成功率。对缺乏放疗设备的医疗单位, 我们可以用NAC代替后装腔内治疗。

     

    Abstract: Objective To determine the role of neoadjuvant chemotherapy (NAC)) before radical Wertheim hysterectomy. Methods Fouty-nine previously untreated patients with stage Ib~IIb were enrolled in the study. Results The overall clinical response rate was 61.22% . Pathologic complete responses were found in 2 patients ( 4.08% ). The median survival time was 44 months in NAC treatment patients and as for survival time and survival rate there is no significant difference between two groups. Conclusion These prel...

     

/

返回文章
返回